Literature DB >> 10421673

Hepatitis B therapy: the plot thickens.

A H Malik1, W M Lee.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10421673     DOI： 10.1002/hep.510300238

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  5 in total

1.  Transformation of hepatitis B serologic markers in babies born to hepatitis B surface antigen positive mothers.

Authors:  Jian-She Wang; Hui Chen; Qi-Rong Zhu
Journal:  World J Gastroenterol       Date:  2005-06-21       Impact factor: 5.742

2.  High rates of progressive hepatic functional deterioration whether lamivudine therapy is continued or discontinued after emergence of a lamivudine-resistant mutant: a prospective randomized controlled study.

Authors:  Yoon Jun Kim; Byeong Gwan Kim; Jun-Oh Jung; Jung-Hwan Yoon; Hyo-Suk Lee
Journal:  J Gastroenterol       Date:  2006-03       Impact factor: 7.527

3.  Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.

Authors:  D J Tenney; S M Levine; R E Rose; A W Walsh; S P Weinheimer; L Discotto; M Plym; K Pokornowski; C F Yu; P Angus; A Ayres; A Bartholomeusz; W Sievert; G Thompson; N Warner; S Locarnini; R J Colonno
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

4.  Fatal liver failure due to reactivation of lamivudine-resistant HBV mutant.

Authors:  Tatehiro Kagawa; Norihito Watanabe; Hisashi Kanouda; Ichiro Takayama; Tadahiko Shiba; Takashi Kanai; Kazuya Kawazoe; Shinji Takashimizu; Nobue Kumaki; Kazuo Shimamura; Shohei Matsuzaki; Tetsuya Mine
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

5.  Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.

Authors:  Eneida A Santos; Michel V F Sucupira; Juçara Arabe; Selma A Gomes
Journal:  BMC Infect Dis       Date:  2004-08-31       Impact factor: 3.090
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.